PT - JOURNAL ARTICLE AU - TAKEO FUJII AU - NAOKI NISHIMURA AU - KEVIN Y. URAYAMA AU - HISAKO KANAI AU - HIROMASA ISHIMARU AU - JUNKO KAWANO AU - OSAMU TAKAHASHI AU - HIDEKO YAMAUCHI AU - TERUO YAMAUCHI TI - Differential Impact of Fosaprepitant on Infusion Site Adverse Events Between Cisplatin- and Anthracycline-based Chemotherapy Regimens DP - 2015 Jan 01 TA - Anticancer Research PG - 379--383 VI - 35 IP - 1 4099 - http://ar.iiarjournals.org/content/35/1/379.short 4100 - http://ar.iiarjournals.org/content/35/1/379.full SO - Anticancer Res2015 Jan 01; 35 AB - Background: Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. Patients and Methods: 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. Results: 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). Conclusion: Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.